Dova Pharmacuet (NASDAQ:DOVA) announced its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.08, Bloomberg Earnings reports.

Dova Pharmacuet (DOVA) traded down 2.15% on Thursday, reaching $18.20. 96,154 shares of the company traded hands. The stock’s market capitalization is $454.82 million. Dova Pharmacuet has a 52-week low of $12.03 and a 52-week high of $28.59. The firm has a 50 day moving average price of $21.16 and a 200 day moving average price of $21.16.

WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/dova-pharmacuet-dova-releases-quarterly-earnings-results-misses-estimates-by-0-08-eps/1470991.html.

In other news, CEO Alex Sapir purchased 20,100 shares of the stock in a transaction that occurred on Wednesday, July 5th. The stock was acquired at an average price of $17.00 per share, with a total value of $341,700.00. Following the purchase, the chief executive officer now owns 20,100 shares in the company, valued at approximately $341,700. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven M. Goldman purchased 72,000 shares of the stock in a transaction that occurred on Wednesday, July 5th. The stock was purchased at an average cost of $17.94 per share, with a total value of $1,291,680.00. Following the purchase, the director now owns 42,000 shares in the company, valued at approximately $753,480. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 101,800 shares of company stock worth $1,798,280.

DOVA has been the topic of several recent analyst reports. Jefferies Group LLC initiated coverage on shares of Dova Pharmacuet in a report on Monday, July 24th. They set a “buy” rating and a $30.00 price objective on the stock. Leerink Swann initiated coverage on shares of Dova Pharmacuet in a report on Monday, July 24th. They set a “market perform” rating and a $24.00 price objective on the stock. Finally, J P Morgan Chase & Co initiated coverage on shares of Dova Pharmacuet in a report on Monday, July 24th. They set an “overweight” rating and a $35.00 price objective on the stock.

Dova Pharmacuet Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Receive News & Ratings for Dova Pharmacuet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmacuet and related companies with Analyst Ratings Network's FREE daily email newsletter.